Degarelix: a guide to its use in advanced prostate cancer

Drugs & Therapy Perspectives, 04/05/2012

Lyseng-Williamson KA - Degarelix, a gonadotropin–releasing hormone (GnRH) receptor antagonist, is indicated as an androgen–deprivation therapy in men with advanced hormone–dependent prostate cancer. It effectively induces and maintains suppression of serum testosterone to castration levels and has an acceptable tolerability profile. Relative to leuprolide, degarelix is associated with more rapid induction of testosterone and prostate–specific antigen (PSA) suppression without the testosterone surges associated with GnRH receptor agonists, and a potentially lower risk of the combined endpoint of PSA progression and death.

Print Article Summary Cat 2 CME Report